Key concepts in the management of difficult hemorrhagic cases

Pharmacotherapy

Volumn 27, Issue 9 II SUPPL., 2007, Pages

  MacLaren, Robert ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Anticoagulant; Bleeding; Coagulopathy; Hemorrhage; Hemostasis; Intracerebral; Surgery; Warfarin

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; VITAMIN K GROUP; VON WILLEBRAND FACTOR;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL FEATURE; CRYOPRECIPITATE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; REVIEW; THROMBOELASTOGRAPHY; THROMBOSIS;

EID: 34548331718     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.9part2.93s     Document Type: Review

References (54)

1. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007;82:82-92.
2. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006;37:256-62.
3. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4.
4. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004;63:1059-64.
5. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006;66:1175-81.
6. Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006;37:151-5.
7. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006;37:1465-70.
8. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:S287-310.
9. Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol 2005;4:662-72.
10. Steiner T, Kaste M, Forsting M, et al. Recommendations for the management of intracranial haemorrhage. I. Spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006;22:294-316.
11. Badjatia N, Rosand J. Intracerebral hemorrhage. Neurologist 2005;11:311-24.
12. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007;21:37-48.
13. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006;4:1853-63.
14. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (STICH): a randomised trial. Lancet 2005;365:387-97.
15. Al-Shahi R, You H. Hemostatic drug therapies for acute, nontraumatic intracerebral hemorrhage. Stroke 2006;37:204-5.
16. Shander A, Goodnough LT. Update on transfusion medicine. Pharmacotherapy 2007;27(9 pt 2):S57-68.
17. Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm? Crit Care Med 2006;34:S170-3.
18. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006;4:967-70.
19. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005;115:455-9.
20. Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy. Pharm Ther 2005;30:644-58.
21. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monitor 2002;8:CS98-100.
22. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003;14:469-77.
23. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884-8.
24. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004;79:1495-500.
25. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003;98:737-40.
26. Roitberg B, Emechebe-Kennedy O, min-Hanjani S, Mucksavage J, Tesoro E. Human recombinant factor VII for emergency reversal of coagulopathy in neurosurgical patients: a retrospective comparative study. Neurosurgery 2005;57:832-6.
27. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005;2:263-7.
28. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006;26:1091-8.
29. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
30. Novo Nordisk. Phase 3 stroke trial shows that NovoSeven® reduces bleeding in the brain, but does not improve long-term clinical outcomes [press release]. Bagsvaerd, Denmark; February 26, 2007. Available from http.//www.novonordisk.com/include/asp/exe_news_attachment.pdf?sAttachmentGU1D= 2da99205-6e99-4933-9174-2bc77ad5cc4d. Accessed February 26, 2007.
31. MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion 2005;45:1434-42.
32. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
33. Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke 2006;37:2751-8.
34. Zimmerman L. Causes and consequences of critical bleeding and mechanisms of blood coagulation. Pharmacotherapy 2007;27(9 pt 2):S45-56.
35. Hartmann M, Sucker C, Boehm O, Koch A, Loer S, Zacharowski K. Effects of cardiac surgery on hemostasis. Transfus Med Rev 2006;20:230-41.
36. Erstad BL. Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery. Ann Pharmacother 2001;35:1075-84.
37. Erstad BL. Systemic hemostatic medications for reducing surgical blood loss. Ann Pharmacother 2001;35:925-34.
38. Rossaint R, Cerny V, Coats TJ, et al. Key issues in advanced bleeding care in trauma. Shock 2006;26:322-31.
39. Levy JH. Hemostatic agents. Transfusion 2004;44:558-62.
40. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44:1039-46.
41. Salooja N, Perry DJ. Thromboelastography. Blood Coagul Fibrinolysis 2001;12:327-37. (Erratum in Blood Coagul Fibrinolysis 2002;13:75.)
42. Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. Guidelines on the management of massive blood loss. Br J Haematol 2006;135:634-41.
43. Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth 2000;85:487-91.
44. O'Shaughnessy DF, Atterbury C, Bolton MP, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11-28.
45. Laupacis A, Fergusson D, for the International Study of Perioperative Transfusion (ISPOT) Investigators. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg 1997;85:1258-67.
46. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007;7:185-94.
47. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
48. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-9.
49. Carless PA, Moxey AJ, Stokes BJ, Henry DA. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials [online exclusive article]. BMC Cardiovasc Dis 2005;5:19. Available from http://www.biomedcentral.com/1471-2261/ 5/19.
50. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005;45:26-34.
51. Aggarwal A, Malkovska V, Catlett JP, Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage [online exclusive article]. Thromb J 2004;2:9. Available from http://www.thrombosisjournal.com/content/2/1/9.
52. van de Garde EM, Bras LJ, Heijmen RH, et al. Low-dose recombinant factor VIIa in the management of uncontrolled postoperative hemorrhage in cardiac surgery patients. J Cardiothorac Vasc Anesth 2006;20:573-5.
53. McCall P, Story DA, Karapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Can J Anaesth 2006;53:926-33.
54. Bishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 2006;81:875-9.